This company has been marked as potentially delisted and may not be actively trading. Intensity Therapeutics (INTS) News Today Add Compare Share Share Headlines Stock AnalysisBuy This Stock INTS Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 Time Period Intensity Therapeutics Inc.: Intensity Therapeutics Reports INVINCIBLE-4, Presurgical Triple-Negative Breast Cancer Study UpdateSeptember 10, 2025 | finanznachrichten.deIntensity Therapeutics pauses new patient enrollment in INVINCIBLE-4 trialSeptember 10, 2025 | msn.comIntensity Therapeutics Reports INVINCIBLE-4, Presurgical Triple-Negative Breast Cancer Study UpdateSeptember 10, 2025 | prnewswire.comIntensity Therapeutics, Inc. to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 2, 2025 | prnewswire.comIntensity Therapeutics price target lowered to $1.50 from $4 at BenchmarkAugust 20, 2025 | msn.comBrookline Capital Upgrades Intensity Therapeutics (INTS)August 14, 2025 | msn.comIntensity Therapeutics upgraded to Buy from Hold at BrooklineAugust 12, 2025 | msn.comIntensity Therapeutics Inc.: Intensity Therapeutics, Inc. Regains Compliance with Nasdaq's Minimum Stockholders' Equity RequirementAugust 12, 2025 | finanznachrichten.deIntensity Therapeutics regains Nasdaq complianceAugust 12, 2025 | msn.comIntensity Therapeutics regains compliance with Nasdaq requirementAugust 12, 2025 | msn.comIntensity Therapeutics, Inc. Regains Compliance with Nasdaq's Minimum Stockholders' Equity RequirementAugust 12, 2025 | prnewswire.comIntensity Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateAugust 7, 2025 | prnewswire.comIntensity Therapeutics, Inc. Raises $6.6 Million from At The Market Offering (ATM) Stock Sales in July 2025August 4, 2025 | prnewswire.comIntensity Therapeutics Inc.: Intensity Therapeutics, Inc. Announces that INT230-6 Achieved 100% Complete Response Rate in Preclinical Models of Malignant Peripheral Nerve ...July 2, 2025 | finanznachrichten.deIntensity Therapeutics, Inc. Announces that INT230-6 Achieved 100% Complete Response Rate in Preclinical Models of Malignant Peripheral Nerve Sheath Tumors (MPNST) - Seeking AlphaJuly 2, 2025 | seekingalpha.comIntensity Therapeutics, Inc. Announces that INT230-6 Achieved 100% Complete Response Rate in Preclinical Models of Malignant Peripheral Nerve Sheath Tumors (MPNST)June 30, 2025 | prnewswire.comINTS - Intensity Therapeutics Inc Valuation - MorningstarJune 27, 2025 | morningstar.comMIntensity Therapeutics announces public offering of common stockJune 13, 2025 | investing.comIntensity Therapeutics, Inc. Announces Pricing of Public OfferingJune 11, 2025 | prnewswire.comIntensity Therapeutics, Inc. Announces Proposed Public Offering of Common StockJune 11, 2025 | prnewswire.comIntensity Therapeutics, Inc. Announces Patients Receiving INT230-6 Prior to the Start of Standard-of-Care May Achieve High Levels of Tumor Necrosis in the Ongoing Randomized Controlled Phase 2 INVINCIBLE-4 StudyJune 11, 2025 | prnewswire.comIntensity Therapeutics, Inc.'s Phase 3 INVINCIBLE-3 Sarcoma Study Selected for Presentation at the American Society of Clinical Oncology (ASCO) 2025 Annual MeetingMay 29, 2025 | prnewswire.comIntensity Therapeutics, Inc. to Collaborate with Author, Model, Executive Producer, Speaker and Breast Cancer Survivor Christine Handy to Raise Patient Awareness of Early-Stage Breast Cancer Treatment Options on the HorizonMay 28, 2025 | prnewswire.comIntensity Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 13, 2025 | prnewswire.comIntensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Receive European Medicines Agency Authorization to Initiate Phase 2 INVINCIBLE-4 (SAKK/66/22) Study for INT230-6 in the Treatment of Presurgical Triple-Negative Breast Cancer in FranceMay 6, 2025 | prnewswire.comIntensity Therapeutics announces $2.35M public offeringApril 26, 2025 | markets.businessinsider.comIntensity Therapeutics, Inc. Announces $2.35 Million Public OfferingApril 25, 2025 | prnewswire.comIntensity Therapeutics files to sell 4.26M shares of common stockApril 23, 2025 | markets.businessinsider.comIntensity Therapeutics Inc.: Intensity Therapeutics Reports 2024 Year End Financial Results and Provides Corporate UpdateMarch 15, 2025 | finanznachrichten.deIntensity Therapeutics Reports 2024 Year End Financial Results and Provides Corporate UpdateMarch 13, 2025 | prnewswire.comDrug Monitoring Committee Authorizes Continuation of Intensity Therapeutics' Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") Following Periodic ReviewJanuary 28, 2025 | prnewswire.comAlliance Global Partners Initiates Coverage of Intensity Therapeutics (INTS) with Buy RecommendationJanuary 14, 2025 | msn.comIntensity Therapeutics Provides Business Update Highlighting Key Achievements with Lead Drug Candidate INT230-6January 10, 2025 | prnewswire.comIntensity Therapeutics files to sell 1.24M shares of common stock for holdersDecember 14, 2024 | markets.businessinsider.comIntensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Present Phase 2 Data in Presurgical Breast Cancer from the completed INVINCIBLE-2 Study, and an Overview of the Ongoing Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial, INVINCIBLE-4 (SAKK 66/22), at the 2024 San Antonio Breast Cancer Symposium (SABCS)December 12, 2024 | prnewswire.comPromising Clinical Progress and Financial Stability Drive Positive Outlook for Intensity Therapeutics, Inc.November 22, 2024 | markets.businessinsider.comIntensity Therapeutics, Inc. Announces Pricing of $3 Million Registered Direct Offering and Concurrent Private PlacementNovember 21, 2024 | prnewswire.comIntensity Therapeutics presents INT230-6 Phase 1/2 daya in SarcomaNovember 18, 2024 | markets.businessinsider.comIntensity Therapeutics Presents INT230-6 Phase 1/2 Data in Sarcoma and an Overview of its Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society Meeting (CTOS)November 18, 2024 | prnewswire.comIntensity Therapeutics Inc.: Intensity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNovember 16, 2024 | finanznachrichten.deIntensity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNovember 13, 2024 | prnewswire.comIntensity Therapeutics Selected for Oral Podium Presentation in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society (Sarcomas) MeetingNovember 8, 2024 | prnewswire.comHC Wainwright & Co. Initiates Coverage of Intensity Therapeutics (INTS) with Buy RecommendationOctober 31, 2024 | msn.comIntensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Announce the First Patient Dosed in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 / SAKK 66/22)October 31, 2024 | prnewswire.comIntensity Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 4, 2024 | prnewswire.comIntensity Therapeutics, Inc. (INTS)August 15, 2024 | finance.yahoo.comIntensity Therapeutics Inc.: Intensity Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate UpdateAugust 9, 2024 | finanznachrichten.deIntensity Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate UpdateAugust 8, 2024 | prnewswire.comIntensity Therapeutics, Inc. Announces First Patient Dosed in its Global Randomized, Phase 3 Study (INVINCIBLE-3) in Metastatic Soft Tissue SarcomaJuly 9, 2024 | prnewswire.comIntensity Therapeutics, Inc. Announces the Appointment of Thomas Dubin to Its Board of DirectorsMay 15, 2024 | prnewswire.com Get Intensity Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for INTS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. INTS Media Mentions By Week INTS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. INTS News Sentiment▼1.891.02▲Average Medical News Sentiment INTS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. INTS Articles This Week▼11▲INTS Articles Average Week Get the Latest News and Ratings for INTS and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Intensity Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies PDSB News Today MDCX News Today RNXT News Today ELUT News Today ANVS News Today CALC News Today BRNS News Today LTRN News Today BTAI News Today ADAP News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:INTS) was last updated on 9/29/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | Sponsored2013 Bitcoin miner reveals his trading system (free)There are 18,347 cryptocurrencies in the market right now. 99% of them will fail. And trying to pick winner...Crypto Swap Profits | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Intensity Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Intensity Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
